Biotech news, week of November 2, 2026

Machine summary The FDA has approved a generic version of Gilead Sciences' lenacapavir, the branded twice-yearly HIV PrEP injection sold as Yeztugo, according to MedPage Today and STAT News. MedPage Today reports the generic cannot be sold in the United States because the branded product, approved last year, remains patent-protected there, and that the U.S. list price before insurance is $28,218 a year against an expected $40 per person per year in 120 low- and middle-income countries. The report states the shots nearly eliminated new infections in two studies of people at high risk.

1. The shots nearly eliminated new infections in two studies of people at high risk, MedPage Today reports.
2. Gilead Sciences' branded version, approved last year, carries a U.S. list price of $28,218 a year before insurance, and the generic cannot be sold in the U.S. because the brand remains patent-protected, per MedPage Today.
3. WHO figures cited in the report put 41 million people worldwide living with HIV last year and 570,000 deaths from HIV-related causes.

Reported by STAT News and MedPage Today.

• Gilead Sciences
• generic lenacapavir
• Yeztugo (lenacapavir)

Machine summary The ministry said the change is expected to bring clearance closer to manufacturing and distribution sites and reduce inland transport distances.

1. The proposal adds nine inland container depots: Sonipat, Piyala and Harsaru in Haryana; Dadri in Uttar Pradesh; Gandhidham/Mundra in Gujarat; Sanath Nagar and Thimmapur in Telangana; and Whitefield in Bengaluru, Karnataka.
2. Reports say the proposed list also includes the SEZ at Bommasandra, Karnataka, and the Noida International Airport, which lies in Uttar Pradesh, for drug air imports.
3. Existing authorised gateways named in the reports include ICDs at Dhannad and Tihi in Indore, Madhya Pradesh, plus airports already notified for drug import.

Reported by Business Standard and health.economictimes.indiatimes.com.

• Medical devices
• Noida International Airport
• Drugs

Reports ran between 12:05 and 22:18 UTC on Nov 5.

The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

Reported by financialcontent.com and stratfordbeaconherald.com.

• Aurora Cannabis Inc.

Reports ran from 21:38 UTC on Nov 5 to 16:42 UTC on Nov 6.

The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

Reported by MedPage Today and GEN.

• PFAS
• ER-negative breast cancer

Machine summary Elanco reported innovation revenue of $328 million in Q3 2026, up 40% year over year, led by what management calls the Big 6 portfolio, and raised its full-year 2026 innovation revenue target to $1.275 billion. Adjusted EPS of $0.27 was 42% above the prior year and adjusted gross margin expanded 300 basis points to 56.1%, which the company attributed to product mix and pricing. Yahoo Finance reported the shares rose 7.6% on November 6, 2026.

1. Elanco reported Q3 2026 revenue of $1.265 billion, up 11% reported and 9% in organic constant currency terms, according to the company's earnings call
2. Adjusted EPS of $0.27 was 42% above the prior year, with adjusted EBITDA of $243 million (up 23%, a 19.5% margin) and adjusted gross margin of 56.1%, a 300 basis point expansion, the company said
3. Innovation revenue reached $328 million, up 40% year over year, and the company raised its full-year 2026 innovation revenue target to $1.275 billion
4. Credelio Quattro gained 9 percentage points of US market share year over year and, management said, passed Seresto to become the largest US pet health product; Zenrelia added 7 points of US share and reached about 19,000 US veterinary clinics
5. Net leverage fell to 2.9x after $216 million of debt reduction in the quarter and $317 million of gross debt reduction year to date, reaching a sub-3.0x milestone management said came ahead of schedule

Reported by Yahoo Finance, Bloomberg and Motley Fool.

• Credelio Quattro
• Seresto
• Big 6
• Zenrelia
• Elanco Animal Health

Machine summary On its Q3 2026 call, Shoulder Innovations reported a 107 percent increase in research and development spending to $3.2 million, tied to development of the InSet Neo robotics platform. According to the Seeking Alpha report on the results, the company is targeting an FDA submission for InSet Neo in the first half of 2027, while InSet Go has launched.

1. Q3 2026 net revenue was $16.2 million, up 38 percent, which the company attributed to new surgeon additions and greater utilization among existing customers (Q3 2026 earnings call)
2. Full-year 2026 revenue guidance was raised to $68 million–$70 million from a prior range of $67 million–$69 million (Q3 2026 earnings call)
3. Gross margin reached 78.5 percent versus 76.2 percent a year earlier, linked to higher average selling prices and cost-reduction programs (Q3 2026 earnings call)
4. 2,126 implant systems were sold in the quarter, up 34 percent, at an average selling price of $7,616 per system, up 2 percent year over year (Q3 2026 earnings call)
5. R&D expense rose 107 percent to $3.2 million, driven by development of the InSet Neo robotics platform; adjusted EBITDA loss narrowed to $5.5 million from $7.5 million (Q3 2026 earnings call)

Reported by Seeking Alpha and Motley Fool.

• InSet Go
• Shoulder Innovations
• InSet Neo